We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > overall survival

News List

BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma prnasia
January 06, 2020
The results of the study will be submitted for presentation at an upcoming medical congress and shared with the US Food and Drug Administration (FDA) and other health authorities.
TAGRISSO Shows Improved Overall Survival in Trial for NSCLC americanpharmaceuticalreview
August 12, 2019
AstraZeneca announced positive overall survival (OS) results from the Phase III FLAURA trial, a randomized, double-blinded, multicenter trial of TAGRISSO in previously-untreated patients with locally-advanced or ...
Verzenio Demonstrates Significant Improvement in Overall Survival in Breast Cancer Trial americanpharmaceuticalreview
August 01, 2019
Eli Lilly and Company announced Verzenio (abemaciclib) demonstrated a statistically significant improvement in overall survival in the Phase 3 MONARCH 2 clinical trial.
EC approves Merck’s Keytruda for metastatic squamous NSCLC pjavascript:void('body')harmaceutical-technology
March 19, 2019
Micrograph showing a non-small cell lung carcinoma. Credit: Librepath.The European Commission (EC) has approved Merck’s anti-PD-1 therapy Keytruda as a first-line treatment for adults with metastatic squamous non-small cell lung cancer (NSCLC).